Prospective study on the metabolic and linear growth effects of growh hormone treatment in children with Kabuki Syndrome - Metabolic effects of Growth Hormone

Maastricht University Medical Centre0 个研究点开始时间: 2012年3月27日最近更新: 2012年10月9日

试验速览

暂无简介。

•-Children with the MML2 mutation.
•-Children who meet at least four out of five KS characteristics:
•#Facial features: long palpebral fissures with eversion of outer third, arched eyebrows with sparse outer half, prominent and/or misshapen ears, and depressed nasal tip.
•#Skeletal abnormalities.
•#Intellectual disability (mild to moderate).
•#Postnatal short stature.
•#Abnormalities of dermal ridges.
•-Informed consent.
•-Age = four years.
•Are the trial subjects under 18? yes
•Number of subjects for this age range: 20
•F.1.2 Adults (18-64 years) no
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•-Children with a chronological or bone age greater than 8 years for girls and 10 years for boys, because of the influence of puberty.
•-Extremely low dietary intake (less than minimal required intake for age according to WHO criteria).
•-Use of medication that might interfere with growth during GH therapy, such as corticosteroids and sex steroids.

发起方

Maastricht University Medical Centre